Patients (n = 69) with multiple myeloma undergoing peripheral blood stem cell collection (PBSC) were treated with cyclophosphamide and a combination of recombinant methionyl human granulocyte colony-stimulating factor (r-metHuG-CSF, filgrastim) and recombinant methionyl human stem cell factor (r-metHuSCF, ancestim). The objectives of this study were to determine: (1) The proportion of patients reaching a target yield of у5 ؋ 10 6 CD34 + cells/kg in one or two successive large-volume (20 liter) leukapheresis procedures; (2) the optimal collection time for leukapheresis; (3) mobilization kinetics of CD34 + subsets in response to G-CSF/SCF. All patients were mobilized with cyclophosphamide (2.5 g/m 2 ) on day 0 followed by filgrastim (10 g/kg ) plus ancestim (20 g/kg) commencing day 1 and continuing to day 11 or 12. Of the 65 evaluable patients, 57 were considered not heavily pretreated and 96.5% and early progenitors and the ability to predictably schedule leukapheresis.
Results from several clinical trials using high-dose chemotherapy and hematopoietic stem cell transplantation from either an autologous bone marrow [1] [2] [3] or peripheral blood [3] [4] [5] have demonstrated a survival advantage for patients with multiple myeloma compared to results from trials using conventional chemotherapy. Comparisons between PBSC and autologous bone marrow transplantation (ABMT) in this patient population suggest a significantly shorter median duration of neutropenia and superior remission rates and survival with PBSC transplantation compared with ABMT. 6, 7 Successful transplantation requires harvesting of an adequate graft to ensure rapid and sustained recovery of marrow function. Several studies have found a correlation between the number of progenitor cells infused and the time to hematopoietic reconstitution in patients with multiple myeloma. [8] [9] [10] Chemotherapeutic agents including the use of alkylators, such as melphalan, are known to adversely affect CD34
+ progenitor/stem cell yield, 8, 11 and therefore may potentially exclude a large number of candidates who may otherwise benefit from PBSC transplantation. Although a relationship between the rate of engraftment and the yield of CD34 + cells has been demonstrated, [8] [9] [10] 12, 13 others have suggested that the absolute yield of CD34 + cells may be less critical than the infusion of specific primitive subsets of CD34 + cells, eg CD34 + CD33 Ϫ , 14 CD34 + 38 Ϫ , 16 and CD34 + CD90 + . 17 A number of strategies have been evaluated to improve stem/progenitor cell mobilization and yield. [18] [19] [20] [21] [22] [23] [24] [25] Recombi-nant methionyl human stem cell factor (r-metHuSCF, ancestim), the natural ligand for c-kit, has been shown to act synergistically with a variety of other hematopoietic growth factors to increase colony formation in vitro. 26 In preclinical models and clinical trials, synergy with filgrastim enhances PBSC mobilization resulting in faster engraftment at a lower cell dose. [27] [28] [29] [30] Synergy between filgrastim and ancestim may increase not only the absolute number of mobilized CD34
+ cells, but also the relative proportion of uncommitted stem cells and the optimal timing of apheresis. 31, 32 The objectives of this study were to assess the number of patients who achieved a target yield of у5 ϫ 10 6 CD34 + cells/kg in one or two large-volume leukaphereses and examine the kinetics of CD34 + cell mobilization in patients with multiple myeloma, using a combination of cyclophosphamide, filgrastim and ancestim to determine the optimal timing of leukapheresis. We also analyzed the temporal sequence of the appearance of specific subsets of CD34 + cells, including CD34
+ CD133 + , and CD34 + CD90 + using a standard assay.
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Patients and methods
Patient population
The ethics committee for each of the participating institutions approved the protocol and all patients gave written informed consent before any study-related procedures were done. Patients were eligible for study enrolment if they were diagnosed with high-risk multiple myeloma (ie stage I with bone lesions and stage II or III according to the Durie and Salmon classification 34 ), were between 18 and 65 years of age, and had an Eastern Cooperative Oncology Group (ECOG) performance of 0 to 2. The initial accrual for this study was limited to non-heavily pretreated patients, defined as having received р six cycles of prior chemotherapy, with no more than two cycles containing melphalan or nitrosoureas (BCNU). The study was subsequently modified to include patients with more extensive chemotherapy exposure. Laboratory criteria included an absolute neutrophil count (ANC) of у1.5 ϫ 10 9 /l, platelet count у100 ϫ 10 9 /l, serum creatinine р150 mol/l; bilirubin, aspartate transferase (AST), and alanine aminotransferase (ALT) Ͻ twice times the upper limit of normal.
Subjects with MM in persistent relapse (not responsive to second-line chemotherapy), who had a prior bone marrow or PBPC transplant and those with a concurrent malignancy (other than treated basal cell carcinoma of the skin or cervical intra-epithelial neoplasia) were excluded. Due to the possibility of allergic type reactions to r-metHuSCF, subjects with seasonal or recurrent asthma within the previous 10 years, history of anaphylactic-type reactions to food or insect bites, angioedema or recurrent urticaria were also excluded. Other exclusion criteria were uncontrolled infection, significant comorbid conditions, pregnancy, breast-feeding or allergy to Escherichia coli-derived products. Subjects receiving beta adrenergic blocking agents were also excluded.
Study design
This was a phase 2, open-label, multicenter study. The primary endpoint was to determine the proportion of patients who reached the target yield of у5 ϫ 10 6 CD34 + cells/kg in one or two successive large volume leukapheresis procedures The secondary endpoints were to determine the optimal timing for leukapheresis and to determine mobilization kinetics of CD34 + subsets in response to G-CSF/SCF. The mobilization regimen consisted of cyclophosphamide 2.5 g/m 2 intravenously on day 0 followed by 20 g/kg ancestim (Stemgen; Amgen Inc, Thousand Oaks, CA, USA) plus 10 g/kg filgrastim (Neupogen; Amgen Inc) subcutaneously, from day 1 to completion of leukapheresis (day 11 or 12). Patients were premedicated with ranitidine 150 mg, cetirizine 10 mg and salbutamol, two puffs before the administration of ancestim. Leukophereses was performed on days 11 and 12 (if target yield was not reached). A blood volume of 20 l was processed on a COBE Spectra or Baxter Fenwall CS3000 for each leukapheresis.
Peripheral blood samples from day 0 and day 9 to day 12, and leukapheresis samples from day 9 to day 12 were analyzed for CD34
+ cells and CD34 + cell subsets. Leukapheresis samples were diluted 1:10 with phosphate buffered saline containing 10% fetal calf serum.
CD34
+ enumeration and subset analysis All samples were analyzed by a central laboratory using a three-color, single-platform variant of the ISHAGE guidelines. This procedure includes the addition of the viability dye 7-amino actinomycin D (7-AAD), 33, 35, 36 which allows for the measurement of CD34 + cells directly from a flow cytometer without the need for a hematology analyzer, and a direct assessment of total leukocyte and CD34
+ cell viability in a single tube. Details of the methodology have been previously described. 33, 36 In brief, StemKIT (Beckman-Coulter/Immunotech, Florida, USA) which uses CD45FITC/CD34PE and FlowCOUNT fluorescent immunospheres were used for determining absolute CD34 + counts. Diluted peripheral blood or leukapheresis product (100 l) was added to 20 l CD45FITC (clone J33)/CD34PE (clone 581) and 20 l 7-AAD (final concentration 1 g/ml). All analyses were performed in duplicate. Tubes were incubated for 15 min at room temperature and red blood cells were lysed with ammonium chloride for 10 min (blood samples only). Leukapheresis samples, which contained few red blood cells, were suspended in phosphate-buffered saline. Samples were stored on ice until analysis (within 1 h). No wash steps were used in the procedure. Immediately before analysis, 100 l FlowCOUNT fluorospheres were added and tubes analyzed on a Beckman-Coulter XL-MCL flow cytometer ( Figure 1 ).
Additional CD34 + subsets analyses of peripheral blood and leukapheresis samples were done on samples from 20 patients, using a three-color modified ISHAGE protocol. 33, 37 The subsets analyzed included CD38 Ϫ (clone T16), CD90 
Bone Marrow Transplantation
For the CD34 + subset three-color assay, CD34FITC and CD45PC5 were combined with one of the following PE labeled subsets: CD38, CD33, CD90, CD133. Diluted peripheral or leukapheresis products (100 L) were added to titrated antibodies and incubated for 20 min at room temperature. Red blood cells were lysed with 2 ml ammonium chloride (as above, blood samples only) followed by two washes with PBS and suspension in PBS. A minimum of 1000 CD34
+ events were collected on each sample. Positive analysis region was determined on autofluorescence of gated CD34 + cells in FL2 channel (PE) on CD34FITC/CD45PC5/unstained PE tube (Figure 2a , histogram 6). All subsequent tubes were analyzed at this cursor setting. Figure 2b shows representative histograms of the four subsets gated on CD34 + cells as defined above.
Statistical analysis
Simple descriptive statistics were used to summarize, (1) The proportion of patients who achieved a target yield of у5ϫ 10 6 CD34 + cells/kg in one or two large volume leukapheresis; (2) The median peripheral blood CD34 + yield to determine optimal collection time for leukapheresis between day 9 and day 13; and (3) Analysis of the mobilization kinetics of CD34 + subsets CD38 Ϫ , CD90 + , CD33 Ϫ , and CD133
+ .
Results
Patient demographics and distribution
A total of 69 patients from eight centers were enrolled in this study, and 65 were evaluable. The baseline demographic and disease states are given in Table 1 . The mobilization regimen was well tolerated with the exception of one patient who had an allergic reaction attributed to the administration of ancestim. This patient was subsequently 
Study endpoints
The primary endpoint of the study was to determine the proportion of patients who achieved a target yield of у5ϫ 10 6 CD34 + cells/kg in one or two large-volume leukapheresis. Of the first 20 patients enrolled (one of whom was classified as heavily pretreated), all achieved the target of у5 ϫ 10 6 CD34 + cells/kg in a single large-volume leukapheresis. The median yield was 48.8 ϫ 10 6 CD34 + cells/kg in one collection (range, 9.1 to 221.2 ϫ 10 6 /kg).
CD34
+ cell yield
Due to the increased number of CD34 + cells obtained in the first 20 subjects, eligibility criteria were expanded to allow patients who had received extensive pretreatment before transplantation to enroll. In the second stage of the study, a further 49 patients were entered with a total of 10 patients being classified as heavily pretreated. Overall, a total of 57 patients were evaluable in the non-heavily pretreated group, with one patient not proceeding to leukapheresis due to an allergic reaction to SCF and one sample not evaluable due to clotting. Of these 57 patients, 55 (96.5%) obtained a target of у5 ϫ 10 6 CD34 + cells/kg in one largevolume aphereses with two patients reaching the target in two large-volume leukapheresis. Median CD34
+ yield in the non-heavily pretreated group was 39.5 ϫ 10 6 CD34 + cells/kg (range, 5.2-221.3 ϫ 10 6 ). Eight of the 10 patients defined as heavily pretreated were evaluable. One patient did not proceed to leukapheresis due to the development of febrile neutropenia after cyclophosphamide, and the other had leukaphereses on days 13, 14 and 15 off study protocol and were therefore excluded from analysis. Three (37.5%) patients achieved the target dose with one large-volume leukapheresis and three (37.5%) patients achieved the target dose in two large-volume leukaphereses. The remaining two (25%) patients achieved a minimum of Ͼ 2 ϫ 10 6
+ cells/kg. Median CD34 + yield in the heavily pretreated group was 5.7 ϫ 10 6 CD34 + cells/kg (range, 2.8-25.3) ( Table 2) . Secondary endpoints included determination of optimal collection time for leukapheresis between days 9 and 13, and analysis of the mobilization kinetics of CD34 + subsets CD38 Ϫ , CD90 + , CD33 Ϫ and CD133 + . The optimum day for leukapheresis, based on peripheral + all peaked at day 11. CD34 + subset CD90 + peaked at day 10 with a slight decrease on day 11 (Table 4) .
Discussion
In our study, 96.9% of evaluable patients (100% in nonheavily pretreated, 75% in heavily pretreated) achieved the target yield of у5ϫ 10 6 CD34 + cells/kg and 98% achieved a 'minimum target' of CD34 + of 2 ϫ 10 6 /kg in a one or two large-volume leukaphereses. These results represent a greater proportion of patients than reported in trials using other cytokines with or without chemotherapy mobilization strategies. In most of these studies, the median number of leukaphereses was two or more. [38] [39] [40] Although the overall patient population in this study was not heavily pretreated, the median absolute yield of CD34 + cells obtained suggests that the mobilization regimen combined with large-volume leukapheresis was a critical factor in harvesting such large numbers of progenitor cells. In a randomized study of patients with multiple myeloma with similar prior chemotherapy, Facon et al 41 showed an increased median yield of CD34
+ cells and a reduced number of leukapheresis procedures in patients receiving ancestim, filgrastim, and cyclophosphamide compared to filgrastim and cyclophosphamide alone. Enhanced CD34
+ mobilization when filgrastim is combined with ancestim, compared to filgrastim alone, has been observed in a number of other studies in breast cancer, 32, 39 non-Hodgkin's lymphoma, 42, 43 and ovarian cancer. 47 Higher yields of CD34 + cells are associated with more rapid hematopoietic recovery in PBSC transplantation, 46 ,47 but combination cytokine therapy including ancestim has yet to demonstrate a significant clinical impact on engraftment kinetics. 32, 40, 41 For neutrophil engraftment, the kinetics of recovery are unlikely to be affected significantly once a CD34 + cell dose exceeds 5 ϫ 10 6 /kg. 46 Others have noted that a CD34
+ cell dose up to 10 ϫ 10 6 /kg has been associated with progressively more rapid platelet recovery. 16 The combination of r-metHuGCSF/r-metHuSCF and cyclophosphamide was well tolerated in the majority of patients. One allergic reaction characterized by wheezing and shortness of breath after r-metHuSCF was noted in our study and has been reported by others. 43 This was not prevented by premedication with ranitidine, cetrizine and salbutamol. Allergic reaction to SCF is postulated to be caused by mast cell stimulation 44, 45 and administration of SCF should be done in a supervised setting.
One potential application of combination cytokine regimens, such as ancestim and filgrastim, may be enhanced mobilization in heavily pretreated patients who might otherwise not be considered candidates for transplantation because of excessive prior alkylator exposure. Tricot et al 8 found in patients with multiple myeloma that a CD34 + 857 Table 4 Subset analysis of CD34 + cells from peripheral blood and leukapheresis samples (n = 20) /kg was obtained in 97% of patients with shorter exposure (12 months of prior chemotherapy), 85% of patients with 13 to 24 months of exposure, and 28% of patients with greater than 24 months of prior therapy. Although the number of heavily pretreated patients in this study, defined as having received greater than six cycles of chemotherapy or more than two cycles containing melphalan or nitrosureas (BCNU), was limited, many of these patients had been exposed to multiple cycles of alkylator therapy (median, 5; range: 3-37). Of the five patients who had received more than 24 months of chemotherapy, three (60%) achieved the target yield and the remaining two (40%) achieved the minimum of 2 ϫ 10 6
CD34
+ cells/kg. One of those patients had 18 cycles of melphalan and had failed filgrastim mobilization on two previous occasions. Although showing delayed release of CD34 + cells into the peripheral circulation, 2.3 ϫ 10 6 CD34 + cells/kg in three leukapheresis procedures were collected and the patient proceeded to infusion and engraftment. Thus, although heavily pretreated patients had lower yields, a proportion of these patients can mobilize adequate grafts and should not necessarily be excluded from PBSC transplantation.
Predictable timing and a reduced requirement for leukapheresis in patients receiving ancestim and filgrastim may be advantageous with respect to the cost and morbidity associated with multiple leukapheresis procedures. 49 Since the absolute number of CD34 + cells in mobilized peripheral blood was increased with the combination of ancestim and filgrastim after chemotherapy, it raises the possibility of successfully collecting an adequate number of PBSC by whole blood donation. 41 Of the nonheavily pretreated
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+ cell count of 2 ϫ 10 6 /kg by donating 500 ml of whole blood and 82% of patients would have obtained the minimum CD34
+ cell number (2 ϫ 10 6 /kg) after donation of 1 liter of whole blood. The feasibility of whole blood donation to engraft patients after myeloablative therapy has previously been demonstrated. 50, 51 Whole blood donation as a source of PBSC has the potential to entirely eliminate the requirement for leukapheresis and avoid the loss of stem cells associated with cryopreservation. 52, 53 In addition to measuring the absolute yield of CD34 + cells, we monitored the kinetics of subsets of CD34 + cells mobilized using this regimen. We observed a temporal increase in all subsets from day 9 to day 11, with the exception of CD90. These results are consistent with previous studies examining the mobilization kinetics of CD90 (Thy-1). /kg. In our study, this particular population of CD34 + CD90 + cells peaked earliest during mobilization with the greatest proportion (median, 50%) on day 9 and the highest absolute number on day 10 as opposed to day 11 for the other subsets analyzed. Previous studies have also demonstrated early mobilization kinetics for this subset using different mobilization regimens. 11 Although early mobilization could have implications for positive selection protocols targeting the CD90 + subset, the difference in absolute number of CD34 + CD90 + on days 9, 10 and 11 (median: 131 vs 147 vs 120 ϫ 10 6 /l) was small and thus unlikely to have any adverse clinical consequences.
In summary, the combination of ancestim and filgrastim in patients with multiple myeloma was highly efficient at mobilizing CD34 + cells and relevant subsets responsible for engraftment. The high yield of CD34 + cells using this combination reduces the number of leukapheresis procedures for most patients and may improve the feasibility of whole blood collection of PBSC. The ability to use this protocol in heavily pretreated patients may enable successful PBSC transplant in otherwise ineligible patients with multiple myeloma. 
